When.com Web Search

  1. Ads

    related to: glp 1 agonist mounjaro definition medical

Search results

  1. Results From The WOW.Com Content Network
  2. Tirzepatide - Wikipedia

    en.wikipedia.org/wiki/Tirzepatide

    [9] [13] In the United States, it is sold under the brand name Mounjaro for diabetes treatment, [9] and Zepbound for weight loss and treatment of obstructive sleep apnea. [10] [17] Tirzepatide is a gastric inhibitory polypeptide analog and GLP-1 receptor agonist. [10]

  3. GLP-1 receptor agonist - Wikipedia

    en.wikipedia.org/wiki/GLP-1_receptor_agonist

    GLP-1 agonists were initially developed for type 2 diabetes. The 2022 American Diabetes Association standards of medical care recommend GLP-1 agonists as a first-line therapy for type 2 diabetes, specifically in patients with atherosclerotic cardiovascular disease or obesity. The drugs were also noted to reduce food intake and body weight ...

  4. What Are GLP-1 Medications & Who Should Use Them? Here ... - AOL

    www.aol.com/glp-1-medications-them-heres...

    GLP-1 medications are drugs that mimic the effects of the GLP-1 hormone, helping regulate blood sugar and reduce appetite. They are primarily used for managing type 2 diabetes but are also ...

  5. Here's How Mounjaro Differs From Ozempic - AOL

    www.aol.com/heres-mounjaro-differs-ozempic...

    What is Mounjaro—and how is different from Ozempic? ... semaglutide, is a GLP-1 receptor agonist, which means it mimics the GLP-1 hormone and triggers insulin to make you feel less hungry, says ...

  6. GLP-1 drugs linked to lower dementia risk, higher risk of ...

    www.aol.com/glp-1-drugs-linked-lower-150000525.html

    A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.

  7. Incretin - Wikipedia

    en.wikipedia.org/wiki/Incretin

    Tirzepatide (Mounjaro) is a potent GIP analog with agonist activity at GIP and GLP-1 receptors. It was approved for the treatment of type 2 diabetes in the United States in May 2022, and for the management of obesity in November 2023.